Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Agios Gets $200m Up Front In New Celgene Deal, Regains AG-120 Rights

May 18 2016

• By Mandy Jackson

business

Related Content

Celgene and Agios to target cancer metabolism in $250 million deal

Apr 16 2010

ASH 2015: First-In-Class Myeloma Highlights

Dec 11 2015

Related Companies

Agios Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Additional Topics

Companies Deals Cancer

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window